GenoLogics says that a growing number of leading-edge research and discovery organisations have chosen its lab informatics platform, Omix, to enable their translational medicine initiatives
Richard Rauscher, director of information technology for Penn State Cancer Institute, commented: "It was crucial for us to choose a solution we can implement quickly across multiple labs, with immediate benefits.
"These systems will assist us in becoming an NCI-designated cancer centre, while enabling our longer term translational medicine vision".
Omix is a research Lims platform optimised for life sciences.
This unique software solution provides an integrating platform that can be scaled across multiple labs providing a common underlying architecture and user interface.
When coupled with Geneus and Proteus, deeply science-purposed applications for genomics and proteomics research, Omix is optimised to manage and integrate clinical and research data associated with translational medicine.
GenoLogics CEO, Michael Ball, said: "Translational medicine holds huge promise for clinical research organisations and drug discovery companies.
"It's great to see evidence that these leading organisations see the value of our platform and recognise its suitability for translational medicine".
Among the organisations chosing Omix are Biogen Idec, University of Virginia, Penn State College of Medicine and Penn State Hershey Medical Center, US NHLBI Proteomics Center - Bethesda, University of Pennsylvania - Institute for Translational Medicine and Therapeutics (Itmat), Scripps Florida, University of Glasgow, and a leading pharmaceutical company.
